SCHEMBL3801185

SCHEMBL3801185

c1ccc(OCC2CCOC2)c(Nc2ncnc3sccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
NPC1 O15118 5/20 0.45
HTT P42858 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MAPK1 P28482 2/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 4/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
TNF P01375 1/20 0.43
NOD1 Q9Y239 1/20 0.43
MKNK2 Q9HBH9 1/20 0.42
MCHR1 Q99705 1/20 0.41
TSHR P16473 1/20 0.40
PIP4K2A P48426 1/20 0.39
EGFR P00533 1/20 0.39
FADS1 O60427 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3794289 0.84 MEN1 (0.49) MEN1KMT2ANPC1HTTSMN1; SMN2
SCHEMBL3798528 0.84 MEN1 (0.49) MEN1KMT2ANPC1HTTSMN1; SMN2
SCHEMBL3801083 0.82 MKNK2 (0.50) HTTSMN1; SMN2LMNARAB9AMAPT
SCHEMBL3797087 0.81 MEN1 (0.51) MEN1KMT2ANPC1HTTSMN1; SMN2
SCHEMBL3798628 0.80 MKNK2 (0.49) MEN1KMT2AHTTSMN1; SMN2MAPK1
SCHEMBL3797996 0.77 MAPK1 (0.63) MEN1KMT2ANPC1HTTSMN1; SMN2
SCHEMBL3796447 0.77 MKNK2 (0.54) MEN1KMT2ARAB9AMKNK2EGFR
SCHEMBL3797986 0.76 MEN1 (0.54) MEN1KMT2ANPC1HTTSMN1; SMN2
SCHEMBL3801794 0.75 MEN1 (0.53) MEN1KMT2ANPC1HTTSMN1; SMN2
SCHEMBL3801680 0.74 MEN1 (0.71) MEN1KMT2ANPC1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US claimed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP claimed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO claimed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO claimed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK MEN1 1106/4885KMT2A 1016/4885NPC1 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.